Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C

BACKGROUND: In January 2015, the first interferon-free direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection was approved for inclusion in Israel’s national basket of health services. During 2015, HCV genotype 1 patients with advanced liver fibrosis (stage F3-F4) were e...

Descripción completa

Detalles Bibliográficos
Autores principales: Avisar, Nitzan, Heller, Yael, Weil, Clara, Ben-Baruch, Aviva, Potesman-Yona, Shani, Oren, Ran, Chodick, Gabriel, Shalev, Varda, Ash, Nachman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Integrative Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618729/
https://www.ncbi.nlm.nih.gov/pubmed/28954630
http://dx.doi.org/10.1186/s13584-017-0172-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618729/
https://www.ncbi.nlm.nih.gov/pubmed/28954630
http://dx.doi.org/10.1186/s13584-017-0172-1

Ejemplares similares